As of 2026-03-08, the EV/EBITDA ratio of Anika Therapeutics Inc (ANIK) is -26.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Anika's latest enterprise value is 145.62 mil USD. Anika's TTM EBITDA according to its financial statements is -5.57 mil USD. Dividing these 2 quantities gives us the above Anika EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 15.4x | 14.8x |
| Forward P/E multiples | 16.5x - 21.0x | 18.8x |
| Fair Price | (0.83) - 8.98 | 3.36 |
| Upside | -105.9% - -36.4% | -76.2% |
| Date | EV/EBITDA |
| 2026-03-03 | -26.86 |
| 2026-03-02 | -26.66 |
| 2026-02-27 | -26.76 |
| 2026-02-26 | -22.70 |
| 2026-02-25 | -17.91 |
| 2026-02-24 | -17.67 |
| 2026-02-23 | -17.86 |
| 2026-02-20 | -17.11 |
| 2026-02-19 | -17.29 |
| 2026-02-18 | -16.82 |
| 2026-02-17 | -16.56 |
| 2026-02-13 | -16.02 |
| 2026-02-12 | -15.63 |
| 2026-02-11 | -16.12 |
| 2026-02-10 | -16.33 |
| 2026-02-09 | -16.07 |
| 2026-02-06 | -16.67 |
| 2026-02-05 | -16.25 |
| 2026-02-04 | -17.21 |
| 2026-02-03 | -15.53 |
| 2026-02-02 | -14.52 |
| 2026-01-30 | -13.48 |
| 2026-01-29 | -13.27 |
| 2026-01-28 | -13.22 |
| 2026-01-27 | -13.27 |
| 2026-01-26 | -13.48 |
| 2026-01-23 | -13.69 |
| 2026-01-22 | -13.90 |
| 2026-01-21 | -14.23 |
| 2026-01-20 | -14.08 |
| 2026-01-16 | -13.69 |
| 2026-01-15 | -14.26 |
| 2026-01-14 | -14.28 |
| 2026-01-13 | -14.31 |
| 2026-01-12 | -13.95 |
| 2026-01-09 | -14.23 |
| 2026-01-08 | -14.31 |
| 2026-01-07 | -15.06 |
| 2026-01-06 | -14.59 |
| 2026-01-05 | -14.10 |
| 2026-01-02 | -13.79 |
| 2025-12-31 | -14.47 |
| 2025-12-30 | -14.31 |
| 2025-12-29 | -14.26 |
| 2025-12-26 | -14.31 |
| 2025-12-24 | -14.13 |
| 2025-12-23 | -13.90 |
| 2025-12-22 | -13.97 |
| 2025-12-19 | -14.36 |
| 2025-12-18 | -14.31 |